RTW Biotech Opportunities (LON: RTW) financial statements
The consolidated income statement, balance sheet and cash flow statement of RTW Biotech Opportunities for its last 5 fiscal years, as filed with the regulator, in millions of US dollars. At the end of fiscal 2025 it had $1,069m in total assets.
Income statement
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Net profit | $245.2m | $34.2m | $83.2m | −$39.4m | −$64.3m |
Balance sheet
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $1,069m | $760.0m | $446.2m | $401.5m | $439.4m |
| Cash | $6.0m | $5.4m | $2.7m | $7.0m | $6.5m |
| Total liabilities | $203.8m | $127.4m | $17.2m | $53.6m | $52.0m |
| Minority interests | $64.3m | $25.7m | $29.7m | $21.8m | $0.0m |
Cash flow statement
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $105.3m | −$124.3m | $33.5m | $10.4m | −$44.9m |
| Financing cash flow | −$12.6m | $97.1m | −$2.1m | $0.0m | $39.1m |
Where each figure comes from
From the annual report RTW Biotech Opportunities files every year in the European single electronic format (ESEF). The filing for each fiscal year: 2025 · 2024 · 2023 · 2022. If an item is not tagged in the filing, it is not in the table. The summary of the last fiscal year is on the RTW Biotech Opportunities page.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.